Ulysses Neuroscience Ltd., an Irish-based Private R&D Organization based in Trinity College Dublin, and FutureNeuro, the Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases hosted at RCSI, today announced a strategic partnership to implement Proteus a project combining expertise in cytoskeletal modulation of synaptic plasticity and disruption of blood brain barrier to advance understanding on the biology of Fragile X Syndrome.
Fragile X Syndrome is caused by a mutation in the FMR1 gene and affects both men and women, but tends to be more common and more severe in males. This disorder is characterized by intellectual disability and atypical social development. Fragile X Syndrome is the most common inherited cause of intellectual disability and affects 1 in 4,000 individuals.
Ulysses Neuroscience has research platforms dedicated to: i) preclinical analysis of cognitive/behavioural alterations and neurophysiological recording; ii) preclinical/clinical biomarker analysis (synaptic plasticity and cytoskeletal dynamics) of proteins and nucleic acids in biological fluids and post-mortem tissues; iii) clinical observational studies for cognitive and behavioural assessments and sampling of biological fluids.
FutureNeuro is the SFI Research Centre for Chronic and Rare Neurological Disease, hosted by RCSI. It has academic partners across the country in Trinity College Dublin, Dublin City University, University College Dublin, NUI Galway, University College Cork and Waterford Institute of Technology. The vision of the centre is to enable people with neurological disorders to live independently.
For more see